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Background: Malaria rapid diagnostic tests (RDT) are used for diagnostic purpose in malaria-endemic areas where
reliable microscopy is not available. Persistence of the antigenaemia causes over-diagnosis and may limit the
usefulness of the RDT in monitoring treatment. In this study, the usefulness of histidine-rich protein-2 (HRP2) and
pan-specific or species-specific Plasmodium lactate dehydrogenase (pLDH) in treatment monitoring of
uncomplicated falciparum malaria was carried out in an endemic setting in Myanmar.
Methods: A prospective longitudinal, single-arm, cohort study was done by microscopy to confirm Plasmodium
falciparum mono-infected cases. After direct treatment with an artemether-lumefantrine combination, patients were
followed up on day 3, 7, 14, 21, 28 and any other day of recurrent fever. Blood film examination and RDT were
carried out on day 0 and all follow-up days.
Results: Out of 77 recruited falciparum cases, 63 became adequate clinical and parasitological response (ACPR)
cases, and 60.3% of them were still positive for HRP2 up to day 28. Eleven out of 12 treatment failure cases (91.6%)
were detected by pan pLDH. The mean duration required to become negative of HRP2 was 20 days (SD ± 6.03) and
that of pan pLDH was six days with or without gametocytes and 3.7 days without gametocytes.
Conclusion: Although treatment monitoring cannot be performed by HRP2, it can be assessed by pan pLDH-based
assay after day 3 if a gametocidal drug has been administered and after day 7 if the presence of gametocytes was
not excluded. The pan pLDH-based assay was a suitable test to monitor the treatment response of uncomplicated
falciparum malaria patients.
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The World Health Organization (WHO) recommends
that malaria case diagnosis and management should be
parasite-based and microscopy is still the cornerstone of
diagnosis and remains the recommended method for
therapeutic monitoring [1,2]. However, the staining
process for malaria microscopy may take up to 60 minutes
and is labour-intensive. Interpretation requires expertise
and sequestered parasites in the deep capillaries cannot be* Correspondence: drmhnyunt@gmail.com; kyaw606@gmail.com
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reproduction in any medium, provided the ordetected by microscopy [3,4]. Also required is well-
maintained equipment, a well-executed quality assurance
system and trained staff.
Many new technologies, including immunochroma-
tographic tests, appear to overcome the limitation of mi-
croscopy [5]. The test can be used easily as point of care
at bedside or under field conditions at the peripheral level
where reliable microscopy is not available [4,5]. It contains
bound antibodies to specific antigens such as histidine-rich
protein-2 (HRP2) (specific to Plasmodium falciparum),
pan-specific or species-specific Plasmodium lactate dehydro-
genase (pLDH) or aldolase, which is specific to all the major
Plasmodium species [6]. The HRP2 is a water-solubletd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ture) gametocytes of P. falciparum [7]. The pLDH [8] is pro-
duced by asexual and sexual stages (gametocytes) of malaria
parasites. Test kits currently available detect pLDH from all
Plasmodium species that infect humans [5,7].
Palmer et al. (1999) study showed that the immuno-
chromatographic assay may be useful in post-treatment
monitoring of malaria [9]. However, HRP2 may persist up
to two weeks after chemotherapy [4,7] and it may be de-
pend on the persistence viable asexual stage parasitaemia
below the detection limit of microscopy [10], type of
monoclonal antibody (IgG or IgM) used in the test [11],
type of anti-malarial drugs used to treat the patient [12]
and strain-specific differences in the antigen antibody
interaction [13]. It is not adequate to give a definite conclu-
sion because of the limited number of studies on detection
of antigen by these rapid assays under field conditions up
to 28 days’ follow up. In this study, HRP2 and pan pLDH-
based immunochromatographic cassette assay was used
for the first time to evaluate the role of these tests in post-
treatment monitoring, according to WHO protocol for the
assessment and monitoring of anti-malarial drug efficacy
for the treatment of uncomplicated falciparum malaria
under field conditions for up to 28 days’ follow up [2,14].
Methods
Areas of study
This prospective longitudinal, single-arm cohort study was
done in Myanmar-Thailand border areas, Myawaddy
Township, Kayin State from October to December 2010.
The Township health profile showed that malaria was the
leading cause of morbidity and mortality in this area from
2007 to 2009 and is defined as a hyper-endemic area [15].
The Myanmar-Thailand border is also one of the suspected
loci for emerging drug resistance to falciparum malaria.
Patients in the study
Sample size is calculated according to the anticipated
proportion table [16] and 73 patients were included in
the study, assuming that anticipated population propor-
tion of clinical failures to artemether-lumefantrine 5%,
confidence level of 95%, and precision of 10%.
Patients were recruited to the study were at least six
years old, had mono-infection with microscopy confirmed
P. falciparum (parasitaemia, 500–100,000 asexual forms
per μl), axillary temperature ≥37.5°C or history of fever
within previous 24 hours, ability to swallow oral medication
and ability and willingness to comply with the study proto-
col for the duration of the study and to comply with the
study visit schedule. Any person who showed presence of
signs and symptoms of severe and complicated falciparum
malaria according to current WHO definitions [2], mixed
Plasmodium species, or other species of Plasmodium, pres-
ence of severe malnutrition, presence of febrile conditionsdue to diseases other than malaria, and pregnancy or lacta-
ting mothers, were excluded from the study.
Ethical consideration
The study was approved by the ethical committee from
Department of Medical Research (Lower Myanmar) and
University of Medicine 1, Yangon. Written informed
consents were taken from all the participants.
Screening and enrolment procedures
The participants were screened by peripheral blood
smear stained by 10% Giemsa and examined by micros-
copy. Individuals who met the inclusion criteria were en-
rolled, tested by HRP2 and panpLDH based RDT, thick
and thin films examination for 3% Giemsa and treated
on site with artemether-lumefantrine (CoartemW). The
patients involved were monitored for a period of 28 days
according to the scheduled visits.
Microscopic blood examination
The microscopic blood film examinations were done
according to WHO recommendations described in “Methods
for surveillance of anti-malarial drug efficacy” [2]. Thick
and thin blood films for parasite count were obtained and
examined at screenings on day 0, 1, 2, 3, 7, 14, 21 and 28 or
on any other day if the patient spontaneously returned and
parasitological reassessment was required. All the slides were
counter-checked by two independent, qualified microscopists
and if a result showed more than 20% discrepancy, an expert
microscopist was requested to check the slide and the average
count of the two similar results was recorded.
Immunochromatographic cassette assay test
In this study, malaria antigen (HRP2 and pan pLDH based)
Pf/Pan immunochromatographic test kit (SDW Bioline, Cat
No 05FK60, Lot No 090007, Expiry date 2011.06.08, Stand-
ard Diagnostics Inc, Korea) was used. Test procedure was
done according to manufacturer’s instruction. Briefly, blood
sample (5 μl) was taken from finger tip by a capillary pip-
ette, and the open end immersed in the blood drop and
then gently released for the pressure to draw blood into the
capillary pipette to sample well. Four drops of assay dilu-
ents were added to the assay diluent well. The result was
read after 15 minutes; never after 30 minutes to avoid false
result. Therapeutic evaluation of the patients was not inter-
fered by the result of this test. Band intensity of the result
was noted as follows: 0 no band (negative), 1+ faint band,
but clearly visible (positive), 2+ medium intensity bands,
stronger than 1+ but less than control band (positive), 3+
equal or stronger than the control band (positive).
Quality control of the test kit
The test kits were stored in a temperature and humidity
control room at the Quality Control Laboratory for
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dical Research (Lower Myanmar). In the field, the test kits
were stored at the recommended temperature and humid-
ity. Temperature and humidity were recorded three times
a day, i e, 6 am, 12 noon and 6 pm by using a thermo hy-
grometer to ensure the recommended temperature and
humidity. After the study, 10 test kits from the field were
randomly selected and tested with the quality control
blood samples that were prepared according to the
methods manual for laboratory quality control testing of
malaria RDT to check the validity of the assay kits [17].
Data analysis
After the study was completed, data were entered onto a
database using double independent data entry by using
Microsoft Excel and SPSS software version 16. Sensitivity,
specificity, positive predictive value, negative predictive
values were calculated as blood film examination was gold
standard. Sensitivity is the probability (percentage) that
patients with the infection (determined by the result of
the reference or ‘gold standard’ test, blood film examin-
ation by microscopy) will have a positive result using the
test under evaluation.
Results
A total of 844 patients were screened by active case de-
tection and malaria parasites were detected in 40.9% of
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Figure 1 Screening algorithm of the study cases. MP =malaria parasite
parasitological failure, ACPR = adequate clinical and parasitological responsof the microscopy positive cases were Plasmodium
vivax; 29.4% (102 cases) were P. falciparum; and, 7.2%
(25 cases) were mixed infection, i.e, P. falciparum and
P. vivax.
Of the P. falciparum mono-infection, 77 participants
were recruited for the study. The screening algorithm of
study cases is shown in Figure 1. Baseline and parasito-
logical characteristics of the study patients are shown in
Table 1. The data was analysed first for treatment failure
patients and then adequate clinical and parasitological
response (ACPR) cases.
Early detection of the treatment failure
The result of HRP2 for all the treatment failure patients
of P. falciparum (n = 4) was positive on day of failure.
However, long-term persistence of HRP2 was observed
before day of treatment failure in all of the cases. Persist-
ence positive of the HRP2 was observed up to the day of
failure. It was difficult to differentiate between the per-
sistence of antigen from newly emergent antigen. Their
band intensity was increased in two failure cases but was
the same as the previous schedule visit in the other two.
In 12 parasite-reappeared cases, there was no persist-
ence positivity of pan pLDH results. Band intensity of
the pan pLDH was decreased on subsequent follow-up
days, a feature which was parallel to the microscopy re-
sult. The reappearance of the band of the pan pLDH
was observed in all parasite-reappeared cases regardlessMixed infection 















, Pv = Plasmodium vivax, Pf = Plasmodium falciparum, LPF = late
e.
Table 1 Baseline and parasitological characteristics of the
study populations
Baseline characteristics on day 0 (N = 77)
Mean age in years 23.83
Range of age in years (minimum, maximum) 6–56
Sex ratio (male/female) 2.08 (52/25)
Mean weight in kg 41.35
Mean height in cm 146.57
Mean temperature (°C) 38.95
History of fever within 24 hours (%) 100
Haemoglobin level (mean, range) 10.7 (6.5–15)
Parasitological characteristics on day 0 (N = 77)
Initial asexual parasitaemia density range (parasites/μl) 580–96000
Mean of initial asexual parasitaemia density (parasites/μl) 15672
Initial Plasmodium falciparum gametocyte carrying cases 22.08% (17)
Range of gametocyte density (per ul) 21–4316
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density was low (31 per μl of blood) (Table 2).
Sensitivity, specificity, positive predictive value and
negative predictive value of the HRP2 and pLDH
In this study, a total of 453 HRP2 and pan pLDH combo
tests were done in 77 uncomplicated falciparum malaria
patients and no invalid result was observed. The sensi-
tivity, specificity, positive predictive value and negative
predictive value of the assay were calculated on day 0
and subsequent follow-up visits up to day 28.
The sensitivity of the HRP2 was higher than that of the
pan pLDH in all follow-up visits. However, pLDH was
more specific than HRP2. The HRP2 had 100% sensitivity
in almost all of the testing times, i.e, day 0 through day 28


















12 D28 0The pLDH had high specificity (73.97–96.87%). The
specificity was increased to 87.10–100% if P. falciparum
gametocytaemia was considered positive for P. falciparum
but it was not significant (χ2 = 0.756, p = 0.9443, 95% CI).
However, if P. falciparum gametocytaemia was con-
sidered positive for P. falciparum, the sensitivity of
the pan pLDH was significantly increased (χ2 = 155.35,
p < 0.0001, 95% CI).
The results of pan pLDH were parallel to the microscopy
result on day 0 and all of the follow-up days (χ2 = 2.853,
p = 0.7227, 95% CI) in all ACPR cases. However, positive
results of HRP2 were significantly higher than of micros-
copy (χ2 = 92.936, p <0.0001, 95% CI) as shown in Figure 2.
Persistence of HRP2 and pan pLDH in ACPR cases
Among 63 ACPR cases, 60.32% were still positive for
HRP2 assay up to day 28. Three of the HRP2 positive
cases showed 3+ band intensity on day 28. Although, the
continuous decreasing of the band intensity of HRP2
was observed in most of the ACPR cases, equal band in-
tensity, i.e, 3+, as occurred on the initial day, could not
exclude the resolving infection.
Regarding the pan pLDH, only 3.17% (n = 2) showed 1+
band intensity on day 28. Without gametocytes, only five
cases of false positive were observed on day 3. There was
no case of more than +1 band intensity in all of the cases,
with or without sexual parasite, on and after day 3.
Persistence of antigenaemia after treatment with the
initial parasite count
Long-term persistence of the false positive was directly
correlated with the initial parasite count in ACPR cases
(p = 0.000 for both HRP2 and pLDH). Initial parasite
count was also correlated with the persistence of higher
band intensity of HRP2 on day 28 as shown in Figure 3.result of the HRP2 and pLDH in parasite reappearance cases
ation RDT result
Pv (/ul) Control HRP2 Pan pLDH
0 3+ 3+ 2+
70 3+ 3+ 1+
82 3+ 0+ 1+
2513 3+ 2+ 3+
762 3+ 1+ 2+
527 3+ 1+ 3+
2535 3+ 0 3+
12891 3+ 1+ 3+
153 3+ 1+ 1+
3339 3+ 2+ 3+
3550 3+ 1+ 1+
31 3+ 0 0
Table 3 Sensitivity, specificity, positive predictive value and negative predictive value of the HRP2 and pan pLDH-based
test (Plasmodium falciparum gametocytaemia was considered negative for P. falciparum)
Day Sensitivity (95% CI) Specificity (95% CI) Positive predictive value Negative predictive value
HRP2 pLDH HRP2 pLDH HRP2 pLDH HRP2 pLDH
D0 100 100 NR2 NR2 100 100 NR3 NR3
(95.3–100%) (95.3–100%) (95.3–100%) (95.3–100%)
D3 100 50 0 73.97 5.19 9.52 NR3 96.43
(39.7–100%) (6.8–93.2%) (0.0–4.9%) (62.4–83.6%) (1.4–12.8%) (1.2–30.4%) (87.7–99.6%)
D7 NR1 NR1 1.32 85.53 0 0 100 100
(0.1–7.1%) (75.6–92.6%) (0–4.8%) (0–28.5%) (2.5–100%) (94.5–100%)
D14 NR1 NR1 9.33 93.33 0 0 100 100
(3.8–18.3%) (85.1–97.8%) (0–5.3%) (0–52.2%) (59.0–100%) (94.9–100%)
D21 100 100 27.40 93.06 3.64 37.50 100 100
(15.8–100%) (29.2–100%) (17.6–39.1%) (84.5–97.7%) (0.4–12.5%) (8.5–75.5%) (83.2–100%) (94.6–100%)
D28 100 88.89 39.44 96.87 4.44 80 100 98.41
(15.8–100%) (51.8–99.7%) (29.0–51.8%) (89.2–99.6%) (0.5–15.2%) (44.4–97.5%) (87.7–100%) (91.5–99.9%)
NR = Not relevant.
1 Sensitivity was not calculated because of no true positive.
2 Specificity was not calculated because of no true negative.
3 NPV was not calculated because of no true negative.
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pLDH after treatment
Among the 63 ACPR cases, a total of 25 cases became
HRP2 negative before day 28 and all 63 cases became
pLDH negative within 28 days. Mean time to become
negative result of HRP2 was 20 days (SD ± 6.03) and
pLDH was six days (±6.31). If gametocytes were consid-
ered positive for P. falciparum, the mean time required to
become negative result of HRP2 was 21 days (SD ± 6.41)





















Day of follow up
Figure 2 Comparison of HRP2 and pLDH result with microscopy in eaFalse positive of the HRP2 and pan pLDH
Day 3 persistence of asexual parasitaemia was detected
in four patients. On day 3, 59 (94%) were HRP2 false
positive. On day 7, 62 (98%) were HRP2 false positive. A
total of 56 (89%) on day 14, 45 (71%) on day 21, and 38
(60%) on day 28 were still positive without asexual para-
sitaemia. If P. falciparum gametocytaemia was consid-
ered positive for P. falciparum, false positive of pLDH
was less than 10%. However, false positive for HRP2 was
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Figure 3 Correlation of persistence of band intensity of HRP2 and pLDH with initial parasite count. Higher initial parasite counts were
correlated with the higher persistence of the band intensity in HRP2-based RDTs.
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for P. falciparum.
Discussion
The therapeutic monitoring and early detection of treat-
ment failure is very important in management of malaria
cases in the era of increasing drug resistant malaria. The
ability of the test to monitor response to therapy is ideal
in malaria-endemic areas, especially where drug resistant
P. falciparum has been documented [18].
HRP2 persistence makes early detection of treatment
failure difficult. The sudden increase of the band inten-
sity of HRP2 on subsequent follow-up visits is an alert
to further investigation to confirm treatment failure.
However, without continuous monitoring of cases by the
recording of band intensity, a definite conclusion cannot
be reached of treatment failure. Moreover, being the
HRP2 produced from P. falciparum only, it was useless
in non-P. falciparum infection [11]. The pan pLDH can
detect all treatment failure cases with a parasite count of
more than 50 per μl. The pan pLDH can detect not only
P. falciparum but also non-P. falciparum infection, but
it cannot differentiate between the two. However, if the
sexual stage parasites were still present on follow-up
visits, and the pLDH test became positive, this can cause
confusion in early detection of the treatment failure [19].
There were many studies focusing on the sensitivity of
pan pLDH. However, the results were varied: one study
in Uganda [20] found that its sensitivity was 95.6%, and
a study in Madagascar [21] found pLDH sensitivity was
97%. In a study in Myanmar using CareStartW, two-line
pan pLDH assay showed sensitivity of 94.7% [22]. In this
study, sensitivity and positive predictive value of HRP2
and pan pLDH were 100% in all of the study cases on
day 0. There was no false negative in both of the assay
on day 0. Sensitivity of the HRP2 was 100% in all of thesubsequent follow-up days up to day 28. The sensitivities
of the pan pLDH assay were varied 50 to 100% in subse-
quent follow-up visits. The sensitivities were increased
up to 80 to 100% if P. falciparum gametocytaemia was
considered positive for P. falciparum, indicating that
persistence gametocytaemia may cause positive result of
pLDH. Therefore, it is necessary to follow the National
Anti-malarial Treatment Guidelines and WHO recom-
mendations, which mention to add a single dose of
primaquine (0.75 mg/kg) as a gametocidal drug to arte-
misinin combination therapy for uncomplicated falci-
parum malaria [23].
The result of pan pLDH was parallel to that of micros-
copy. However, the results of HRP2 cause more false posi-
tives due to the long persistence of antigenaemia on
subsequent follow-up days. The long-term persistence of
HRP2 reduces its usefulness in monitoring the response to
treatment. It was documented that during follow up after
treatment, 98.2%, 94.6%, 92.0% and 73.5% of effectively
treated children were still false-positive by RDT at day 14,
21, 28 and 35, respectively, and this antigenaemia could
persist up to 35 day after treatment [24]. In this study,
more than half of the ACPR cases were still HRP2 positive
on day 28, three of whom were 3+ band intensity. Only 20
cases become HRP2 negative before day 28 and the mean
time required to become HRP2 negative was 20 days. It
was longer than that of pan pLDH, which was six days and
it would be shortened down to 3.7 days if P. falciparum
gametocytaemia was considered positive for P. falciparum.
Other studies showed the median duration for pLDH to
become negative was two days for CareStartW malaria
tests and seven days for OptiMAL-ITW [25].
However, continuous reducing of the band intensity of
HRP2 was observed in most of the ACPR patients.
There were evidence of association of the band intensity
and parasite count [26], a ‘plus system’ was used for
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rectly correlated with the band intensity of the assay.
Moreover, initial parasite count was correlated with the
higher band intensity of the HRP2 test. Therefore, the
band intensity of the HRP2 may be a useful tool to ac-
cess treatment response in uncomplicated falciparum
malaria cases.
The frequent occurrence of false positive results can
lead to unnecessary treatment. This can have several
negative outcomes, including clinicians inappropriately
focusing on malaria, and not identifying the true cause
of illness, and unnecessary exposure to anti-malarials. In
some cases, the inappropriately treated patient may re-
turn with similar symptoms, leading the clinician to
falsely report the presence of parasite drug resistance.
This could lead to the clinician not trusting the efficacy
of the first-line anti-malarial and consequently dispen-
sing the second-line anti-malarial, increasing the cost of
treatment and further delaying appropriate treatment [22].
The treatment failure cases may be due to recrudescense
or re-infection (new infection). However, RDTs cannot
differentiate recrudescence from re-infection among
treatment failure cases as only molecular methods can
differentiate. Moreover, RDTs are designated to detect
malaria infection qualitatively and brand to band quality
variation was common, which could affect the use of
these tests.
Conclusion
In this study, HRP2 had higher sensitivity than pan
pLDH assay. However, specificity was higher in pan
pLDH. The persistence of HRP2 up to day 28 in ACPR
cases causes false positive results and this is the reason
HRP2 is not fit for monitoring treatment response. The
pan pLDH can also detect late parasitological failure and
non-P. falciparum infection during the follow-up period.
The persistence of pan pLDH was shorter in duration
than that of HRP2. The meaningful result of pan pLDH
can be observed in monitoring treatment response in
uncomplicated falciparum malaria patients after day 3 of
artemisinin combination therapy if the gametocidal drug
was added according to the recommendation by WHO
in 2010. Therefore, pLDH is useful for therapeutic moni-
toring of uncomplicated falciparum malaria patients.
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